ASPEN (brensocatib 25 mg)
Trial question
What is the effect of brensocatib in patients with bronchiectasis?
Study design
Multi-center
Double blinded
RCT
Population
Characteristics of study participants
63.0% female
37.0% male
N = 1138
1138 patients (722 female, 416 male).
Inclusion criteria: adult and adolescent patients, aged 12-85 years, with bronchiectasis.
Key exclusion criteria: COPD or asthma if the respiratory symptoms were primarily driven by these diseases; bronchiectasis due to cystic fibrosis; immunodeficiency disorder.
Interventions
N=575 brensocatib (at a dose of 25 mg/day).
N=563 placebo (matching placebo).
Primary outcome
Incidence of annualized rate of pulmonary exacerbations over a 52-week period
1.04
1.29
1.3 events...
1.0 events...
0.6 events...
0.3 events...
0.0 events...
Brensocatib
Placebo
Significant
decrease ▼
Significant decrease in the incidence of annualized rate of pulmonary exacerbations over a 52-week period (1.04 events / y vs. 1.29 events / y; RR 0.81, 95% CI 0.69 to 0.94).
Secondary outcomes
Significant increase in exacerbation-free at week 52 (48.5% vs. 40.3%; RR 1.18, 95% CI 1.04 to 1.34).
Significant decrease in least-squares mean decline in FEV1 at week 52 (24 mL vs. 62 mL; MD -38, 95% CI -65 to -11).
No significant difference in the incidence of annualized rate of severe exacerbations (0.14 events / y vs. 0.19 events / y; RR 0.74, 95% CI 0.52 to 1.06).
Safety outcomes
No significant difference in adverse events and serious adverse events.
Conclusion
In adult and adolescent patients, aged 12-85 years, with bronchiectasis, brensocatib was superior to placebo with respect to the incidence of annualized rate of pulmonary exacerbations over a 52-week period.
Reference
James D Chalmers, Pierre-Régis Burgel, Charles L Daley et al. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2025 Apr 24;392(16):1569-1581.
Open reference URL